OrthoPediatrics Q4 preliminary revenue $31M (+25% YoY); FY22 $122.3M (+25%); guides FY23 $146-149M

ORTHOPEDIATRICS CORP

2022-FY EPS reported $0.06 revenue$122,289,000

Preliminary Q4 2022 net revenue $31.0M, up 25% vs $24.8M in Q4 2021.
Full year 2022 preliminary net revenue $122.3M, up 25% from $98.0M in 2021.
Domestic Q4 revenue +15% YoY; international Q4 revenue +67% YoY.
FY 2023 guidance: net revenue $146M-$149M, implying 20-22% growth.
CEO cites viral respiratory infection disruptions at children's hospitals as a headwind.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ORTHOPEDIATRICS CORP updated its fourth quarter and full year ended December 31, 2022 guidance (initiated).

Period: fourth quarter and full year ended December 31, 2022
Guidance: initiated
Result: preliminary results

Exact text from the filing

On January 9, 2023, OrthoPediatrics Corp. (the "Company”) issued a press release announcing its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2022, providing management's projection of 2023 net revenue and providing a related business update.

View on SEC.gov

Browse all earnings releases →

ORTHOPEDIATRICS CORP filing history →

Source: SEC EDGAR

accession 0001425450-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.